Boston Tech Moderna Put CAR-T in a Vial, and Cambridge Called It a Platform Cambridge-based Moderna unveiled mRNA-6007, an in vivo CAR-T bet on lupus and related autoimmune disease that could make cell therapy less bespoke.
